Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-05-31
2005-05-31
Raymond, Richard L. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S234200, C514S234500, C514S249000, C514S252170, C514S264100, C514S266200, C544S116000, C544S117000, C544S279000, C544S284000, C544S350000
Reexamination Certificate
active
06900220
ABSTRACT:
This invention relates to compounds which are generally alpha-1A/B adrenoceptor antagonists and which are represented by Formula I:wherein Z is —C(O)— or —S(O)2—, X is carbon or nitrogen, Y is carbon, and X—Y considered together are two adjoining atoms of the ring A, said ring being a fused aromatic ring of five to six atoms per ring optionally incorporating one to two heteroatoms per ring, chosen from N, O, or S; and the other substituents are as defined in the specification; or individual isomers, racemic or non-racemic mixtures of isomers, or pharmaceutically acceptable salts or solvates thereof. The invention further relates to pharmaceutical compositions containing such compounds, methods for their use as therapeutic agents, and methods of preparation thereof.
REFERENCES:
patent: 3960861 (1976-06-01), Danilewicz et al.
patent: 4044136 (1977-08-01), Danilewicz et al.
patent: 4686228 (1987-08-01), Campbell et al.
patent: 4766211 (1988-08-01), Zink et al.
patent: 5064833 (1991-11-01), Ife et al.
patent: 6103738 (2000-08-01), Collis et al.
patent: 6337332 (2002-01-01), Carpino
patent: 6492358 (2002-12-01), Sui et al.
patent: 6562854 (2003-05-01), Church et al.
patent: 6566367 (2003-05-01), Bakthavatchalam et al.
patent: 2004/0029859 (2004-02-01), Blagg et al.
patent: 2757925 (1979-06-01), None
patent: 1062357 (1967-03-01), None
patent: WO 98/30560 (1998-07-01), None
patent: WO 00/55143 (2000-09-01), None
Gupta, et al., “Drugs Acting on the Central Nervous System. Syntheses of Substituted Quinazolones and Quanazolines and Triazepino- and Triazocinoquina-zolones,”J. Med. Chem., 1968, 392-395, 11(2).
Leonardi, et al., “Synthesis, Pharmacological Evaluation, and Structure—Activity Relationship and Quantitative Structure—Activity Relationship Studies on Novel Derivatives of 2,4-Diamino-6, 7-dimethoxyquinazoline α1-Adrenoceptor Antagonists”,J. Med. Chem., 1999, 427-437, 42.
Menziani, et al., “Relevance of Theoretical Molecular Descriptors in Quantitative Structure—Activity Relationship Analysis of α1-Adrenergic Receptor Antagonists,”Bioorg., Med. Chem., 1999, 2437-2451, 7(11).
Villalorgo, et al., “Solid-Phase Synthesis of 3H-Quinazolin-4-ones Based on an Aza Wittig-Mediated annulation Strategy”,Synlett, 1998, 1405-1407, 12.
Wollweber, et al., “3-Amino-2H-1,2,4-benzothiadiazin-1, 1-dioxide mit antihypertensiver und potentieller diabetogener Wirkung”,Arzneim.-Forsch., 1981, 279-88, 31(2).
Becker Cyrus Kephra
Caroon Joan Marie
Melville Chris Richard
Padilla Fernando
Pfister Jürg Roland
Green Grant D.
Pfister Gloria
Raymond Richard L.
Syntex (U.S.A.) LLC
Truong Tamthom N.
LandOfFree
Quinazolone derivatives as alpha 1A/B adrenergic receptor... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Quinazolone derivatives as alpha 1A/B adrenergic receptor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Quinazolone derivatives as alpha 1A/B adrenergic receptor... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3402670